Matti Aapro, MD, from the Multidisciplinary Oncology Institute, Genolier, Switzerland, discusses the development of new antiemetics at the European Society for Medical Oncology (ESMO) 2017 in Madrid, Spain. New antiemetics have been developed, for example, NEPA, a combination of an NK receptor antagonist and palonosetron. The development of these will have a big impact on the quality of life of patients.